FDA clearance of Rejoyn the first prescription digital therapeutic authorized in the U.S. for the treatment of major depressive disorder – Otsuka
Otsuka Pharmaceutical, Co. Ltd. and Click Therapeutics, Inc., announce that the FDA has cleared Rejoyn (developed as CT-152), the first prescription digital therapeutic authorized in the U.S. for… read more.
